What is Imbruvica?

Imbruvica (ibrutinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

buy Imbruvica 140 is used to treat certain types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia (CLL)/small buy lymphocytic lymphoma (SLL) in people with or without 17p deletion.

online Imbruvica 140mg is also used to treat marginal cell lymphoma and chronic graft-versus-host disease. It is sometimes given when other medicines have not been effective.

Imbruvica was approved to treat mantle cell and marginal lymphomas by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, tumors responded to this medicine. However, it has not been shown that ibrutinib 140 can improve symptoms or lengthen survival time in people with this type of lymphoma.

How to use Imbruvica Capsule

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.

How Imbruvica Capsule works

Imbruvica 140mg Capsule is a Bruton's tyrosine kinase inhibitor. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

IBRUTINIB COMMON SIDE EFFECTS :

pale skin, easy bruising or bleeding; fever, chills, flu symptoms;nausea, diarrhea; tired feeling; rash; or muscle pain, bone pain.

Stop using Imbruvica and call your doctor at once if you have:

chest pain and severe dizziness, fast or irregular heartbeats, trouble breathing, feeling like you might pass out;
fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing;
severe weakness or dizziness, confusion, problems with speech, prolonged headache;

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects.

Dosage

Mantle Cell Lymphoma and Marginal Zone Lymphoma

The recommended dose of IMBRUVICA for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström's Macroglobulinemia

The recommended dose of IMBRUVICA for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
The recommended dose of IMBRUVICA for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.